SpyBiotech Company
SpyBiotech Operators of a biotechnology platform intended to generate next-generation vaccines.The company's biotechnology platform develops bonding vaccines which are made from the proprietary protein superglue which is used to bond antigens to viruses and other particles to make vaccines, enabling medical institutions and research centers with a new and modified technology to develop vaccines which give better results in lesser time.
Founded Date:
2017-01-01
Total Funding:
37490885
Funding Status:
Early Stage Venture
Last Funding Type:
Series A
Investors Number:
5
Last Funding Date:
2021-02-10
Industry:
Atrificial Vectors and Immune Cells
Headquarters:
Oxford, Oxfordshire, United Kingdom
Estimated Revenue:
Less than $1M